期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

达沙替尼致严重胸腔积液1例 被引量：3

下载PDF
导出
摘要 1临床资料 患者,男,49岁,为治疗慢性粒细胞白血病（CML）,自2012年1月17日开始口服达沙替尼100 mg·d-1,1次·d-1。血常规逐渐恢复正常,经骨穿检查骨髓为缓解状态,融合基因BCR-ABL转阴。患者服药约5个月后无明显诱因出现双侧胸腔积液,当地医院予以抽胸水及抗感染治疗后好转。因病情需要,患者短暂停药3 d后继续口服达沙替尼,半个月后出现＂胸闷、憋气加重＂症状,
作者 陈燕琴 丰明星 韩娜 李艳丽 赵伟伟
机构地区 中国人民解放军第
出处 《中南药学》 CAS 2014年第8期831-831,共1页 Central South Pharmacy
关键词 达沙替尼 胸腔积液 药品不良反应
分类号 R969.3 [医药卫生—药理学]
  • 相关文献

参考文献4

  • 1Das J, Moquin RV, Lin J, et al. Discovery of 2-amino- heteroaryl-benzothiazole-6-anilides as potent p561ck inhibitors [J]. BioorgMedChemLett, 2003, 13 ( 15 ) : 2587-2590.
  • 2Wityak J, Das J, Moquin RV, et al. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56Lck [J]. Bioorg Med Chem Lett, 2003, 13 (22) : 4007-4010.
  • 3江倩.达沙替尼治疗慢性粒细胞白血病研究进展[J].内科急危重症杂志,2012,18(6):325-327. 被引量：10
  • 4Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: acase series [J]. Am J Bespir Crit Care Med, 2007, 176 ( 8 ) : 814-818.

二级参考文献24

  • 1Michael Deininger, Stephen G O'Brien, Francois Guilhot, et al. Inter- national randomized study of interferon vs STI571 (IRIS) 8-Year Fol- low up : sustained survival and low risk for progression or events in pa- tients with newly diagnosed chronic myeloid leukemia in chronic Phase ( CML - CP) treated with imatinib. Blood ( ASH Annual Meet- ing Abstracts) ,2009 (114) : 1126.
  • 2Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett,2007,249 ( 2 ) : 121-132.
  • 3Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004,305 ( 5682 ) : 399-401.
  • 4OHare T,Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant ima- tinib-resistant Abl kinase domain mutants. Cancer Res, 2005,65( 11 ) :4500-4505.
  • 5Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncolo- gist ,2008,13 (4) :424-434.
  • 6Porkka K, Koskenvesa P,Lundan T,et al. Dasatinib crosses the blood- brain barrier and is an efficient therapy for central nervous system Phila- delphia chromosome-positive leukemia. Blood,2008,112(4) : 1005-1012.
  • 7Baccarani M, Rosti G, Saglio G, et al. Dasatinib time to and durability of major and complete cytogenetic response ( MCyR and CCyR ) in patients with chronic myeloid leukemia in chronic phase (CML-CP). ASH Annual Meeting,2008(112) :450.
  • 8Apperley J, Cortes J, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol,2009,27(21 ) :3472-3479.
  • 9Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia,2008,22(12) :2176-2183.
  • 10Kantarjian H,Pasquini R,Levy V,et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily:two-year follow-up of a randomized phase 2 study ( START-R ). Cancer,2009,115 ( 18 ) :4136-4147.

共引文献9

同被引文献18

引证文献3

二级引证文献6

中南药学
2014年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部